About Blueprint Medicines
Blueprint Medicines is a company based in Cambridge (United States) founded in 2008 was acquired by Sanofi in June 2025.. Blueprint Medicines has raised $115 million across 4 funding rounds from investors including Royalty Pharma, Sanofi and TD Securities. The company has 201 employees as of December 31, 2022. Blueprint Medicines has completed 1 acquisition, including Lengo Therapeutics. Blueprint Medicines offers products and services including Avapritinib, Elenestinib, and BLU-808. Blueprint Medicines operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Cambridge, United States
- Employees 201 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Blueprint Medicines Corporation
-
Annual Revenue
$17.31 M-92as on Dec 31, 2023
-
Net Profit
$-67.09 M87as on Dec 31, 2024
-
EBITDA
$80.32 M116as on Dec 31, 2024
-
Total Equity Funding
$115 M (USD)
in 4 rounds
-
Latest Funding Round
$1.25 B (USD), Post-IPO
Jun 30, 2022
-
Investors
Royalty Pharma
& 14 more
-
Employee Count
201
as on Dec 31, 2022
- Investments & Acquisitions
-
Acquired by
Sanofi
(Jun 02, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Blueprint Medicines
Blueprint Medicines offers a comprehensive portfolio of products and services, including Avapritinib, Elenestinib, and BLU-808. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats systemic mastocytosis and gastrointestinal stromal tumors.
Targets indolent and advanced systemic mastocytosis.
Addresses chronic urticaria and other mast cell diseases.
Unlock access to complete
Unlock access to complete
Leadership Team
55 people
Operations Team
13 people
Human Resources and Administration
12 people
Software Development Team
12 people
Senior Team
12 people
Sales and Marketing
10 people
Area Team
10 people
Product Management Team
9 people
Unlock access to complete
Funding Insights of Blueprint Medicines
Blueprint Medicines has successfully raised a total of $115M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.25 billion completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $1.2B
-
First Round
First Round
(24 May 2012)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2022 | Amount | Post-IPO - Blueprint Medicines | Valuation |
investors |
|
| Nov, 2014 | Amount | Series C - Blueprint Medicines | Valuation | Cowen , Perceptive Advisors |
|
| Jan, 2014 | Amount | Series B - Blueprint Medicines | Valuation | Nextech Invest |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Blueprint Medicines
Blueprint Medicines has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Royalty Pharma, Sanofi and TD Securities. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in marketed and late-stage biopharmaceutical companies.
|
Founded Year | Domain | Location | |
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
US private equity investments are managed by BVF Partners.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Blueprint Medicines
Blueprint Medicines has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Lengo Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Precision medicines for oncology are developed using covalent drug-target technology.
|
2020 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Blueprint Medicines
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Blueprint Medicines Comparisons
Competitors of Blueprint Medicines
Blueprint Medicines operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Blueprint Medicines
Frequently Asked Questions about Blueprint Medicines
When was Blueprint Medicines founded?
Blueprint Medicines was founded in 2008 and raised its 1st funding round 4 years after it was founded.
Where is Blueprint Medicines located?
Blueprint Medicines is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Blueprint Medicines a funded company?
Blueprint Medicines is a funded company, having raised a total of $115M across 4 funding rounds to date. The company's 1st funding round was a Series B of $25M, raised on May 24, 2012.
How many employees does Blueprint Medicines have?
As of Dec 31, 2022, the latest employee count at Blueprint Medicines is 201.
What is the annual revenue of Blueprint Medicines?
Annual revenue of Blueprint Medicines is $17.31M as on Dec 31, 2023.
What does Blueprint Medicines do?
Blueprint Medicines was founded in 2008 and is headquartered in Cambridge, United States. Operations focus on the biotechnology sector, where selective kinase inhibitors are developed for patients with genomically defined cancers. The approach involves analysis of genetic drivers in cancer and other kinase-related diseases, supported by a proprietary library of chemical compounds. Targets that are difficult to drug are addressed through this method.
Who are the top competitors of Blueprint Medicines?
Blueprint Medicines's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Blueprint Medicines offer?
Blueprint Medicines offers Avapritinib, Elenestinib, and BLU-808.
How many acquisitions has Blueprint Medicines made?
Blueprint Medicines has made 1 acquisition, including Lengo Therapeutics.
Who are Blueprint Medicines's investors?
Blueprint Medicines has 15 investors. Key investors include Royalty Pharma, Sanofi, TD Securities, RA Capital, and Perceptive Advisors.